Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Turcot syndrome 1Pancreatic Neoplasms 1Oligoprogressive 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Cancer Patients 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × DEAE-Dextran × Clear all
NCT06359275 2024-06-25

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Fudan University

Phase 2 Recruiting
81 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡